Malaria is a devastating disease that causes significant morbidity and mortality in temperate and tropical regions around the world. Because of the increased prevalence of multidrug-resistant malaria strains, new drugs are urgently required to combat this problem.
In early December, a significant new development was reported by a multidisciplinary team including investigators from the University of South Florida. In a report published in the Proceedings of the National Academy of Sciences, the team describes the efforts to optimize a hit with antimalarial activity into a drug candidate with all the required properties for clinical use to treat malaria. The team is led by Prof. Kip Guy at St. Jude’s Children’s Medical Research Hospital, Dr. David Floyd at Rutgers University, Dr. Joe DeRisi at the University of California-San Francisco and Dr. Dennis Kyle, Distinguished University Health Professor in the College of Public Health at USF.